Racura Oncology Ltd (ASX:RAC)
Australia
· Delayed Price · Currency is AUD 2.460
0.00 (0.00%)
At close: Mar 6, 2026
Racura Oncology Revenue
Racura Oncology had revenue of 788.42K AUD in the half year ending June 30, 2025, a decrease of -56.50%. This brings the company's revenue in the last twelve months to 3.48M, down -46.10% year-over-year. In the fiscal year ending June 30, 2025, Racura Oncology had annual revenue of 6.04M with 24.96% growth.
Revenue (ttm)
3.48M
Revenue Growth
-46.10%
P/S Ratio
128.57
Revenue / Employee
n/a
Employees
n/a
Market Cap
446.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 6.04M | 1.21M | 24.96% |
| Jun 30, 2024 | 4.84M | 1.70M | 54.29% |
| Jun 30, 2023 | 3.13M | 2.43M | 342.83% |
| Jun 30, 2022 | 707.81K | 320.42K | 82.71% |
| Jun 30, 2021 | 387.39K | 228.01K | 143.07% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 96.30M |
| Immutep | 7.92M |
| Opthea | -139.43K |
| Dimerix | 7.42M |
| Orthocell | 9.33M |
| Tetratherix | 2.00M |
| Starpharma Holdings | 14.58M |
| Clarity Pharmaceuticals | 10.58M |